244 related articles for article (PubMed ID: 10593998)
1. Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks? Rotterdam/Leiden Genetics Working Group.
Lodder LN; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Duivenvoorden HJ; Tibben A; Wagner A; van der Meer CA; Devilee P; Cornelisse CJ; Niermeijer MF
J Med Genet; 1999 Dec; 36(12):906-13. PubMed ID: 10593998
[TBL] [Abstract][Full Text] [Related]
2. Psychological impact of receiving a BRCA1/BRCA2 test result.
Lodder L; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Duivenvoorden HJ; Tibben A; Wagner A; van der Meer CA; van den Ouweland AM; Niermeijer MF
Am J Med Genet; 2001 Jan; 98(1):15-24. PubMed ID: 11426450
[TBL] [Abstract][Full Text] [Related]
3. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing.
Lodder L; Frets PG; Trijsburg RW; Tibben A; Meijers-Heijboer EJ; Duivenvoorden HJ; Wagner A; van Der Meer CA; Devilee P; Cornelisse CJ; Niermeijer MF
Eur J Hum Genet; 2001 Jul; 9(7):492-500. PubMed ID: 11464240
[TBL] [Abstract][Full Text] [Related]
4. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
5. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
6. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
7. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
[TBL] [Abstract][Full Text] [Related]
8. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Kuschel B; Lux MP; Goecke TO; Beckmann MW
Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
[TBL] [Abstract][Full Text] [Related]
9. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
[TBL] [Abstract][Full Text] [Related]
10. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
11. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study.
van Oostrom I; Meijers-Heijboer H; Lodder LN; Duivenvoorden HJ; van Gool AR; Seynaeve C; van der Meer CA; Klijn JG; van Geel BN; Burger CW; Wladimiroff JW; Tibben A
J Clin Oncol; 2003 Oct; 21(20):3867-74. PubMed ID: 14551306
[TBL] [Abstract][Full Text] [Related]
12. [Genetic test and prophylactic treatment in breast cancer families].
Miyoshi Y; Noguchi S
Gan To Kagaku Ryoho; 2002 Apr; 29(4):512-22. PubMed ID: 11977534
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer.
van Dijk S; Timmermans DR; Meijers-Heijboer H; Tibben A; van Asperen CJ; Otten W
J Clin Oncol; 2006 Aug; 24(22):3672-7. PubMed ID: 16877736
[TBL] [Abstract][Full Text] [Related]
14. Effects of coping style and BRCA1 and BRCA2 test results on anxiety among women participating in genetic counseling and testing for breast and ovarian cancer risk.
Tercyak KP; Lerman C; Peshkin BN; Hughes C; Main D; Isaacs C; Schwartz MD
Health Psychol; 2001 May; 20(3):217-22. PubMed ID: 11403219
[TBL] [Abstract][Full Text] [Related]
15. Psychological distress and quality of life associated with genetic testing for breast cancer risk.
Smith AW; Dougall AL; Posluszny DM; Somers TJ; Rubinstein WS; Baum A
Psychooncology; 2008 Aug; 17(8):767-73. PubMed ID: 17992698
[TBL] [Abstract][Full Text] [Related]
16. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rebbeck TR
J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; van Geel B; van Putten WL; Henzen-Logmans SC; Seynaeve C; Menke-Pluymers MB; Bartels CC; Verhoog LC; van den Ouweland AM; Niermeijer MF; Brekelmans CT; Klijn JG
N Engl J Med; 2001 Jul; 345(3):159-64. PubMed ID: 11463009
[TBL] [Abstract][Full Text] [Related]
19. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with decisions about clinical BRCA1/2 testing.
Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
